In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation

  1. January 10, 2024

    Union Funds Exit Amgen, Teva Antitrust MDL

    Teva Pharmaceuticals has settled its differences with the union funds making up the indirect purchase class in multidistrict litigation accusing it of hatching an illegal deal to remove a generic calcium-control drug from the market.

  2. April 06, 2023

    Del. Judge Certifies Appeal In Amgen, Teva Sensipar Case

    A Delaware federal judge Thursday denied Amgen and Teva's request for another shot at an immediate appeal of a prior judge's refusal to toss a case accusing them of cutting an illegal deal to remove a generic calcium control drug from the market, but will let them appeal his order.

  3. March 03, 2023

    Amgen, Teva Want Another Shot At Quick Sensipar Appeal

    Amgen and Teva told a Delaware federal court it has the authority to grant their request for an immediate appeal of a prior judge's refusal to toss a case accusing them of cutting an illegal deal to remove a generic calcium control drug from the market.

  4. July 24, 2020

    Judge Advises Freeing Amgen, Teva From Suits Over Sensipar

    A Delaware federal judge has recommended the dismissal of two antitrust class actions against pharmaceutical giants Amgen and Teva Pharmaceuticals over their agreement to pull a generic version of a calcium control drug off the market, saying the lawsuits failed to properly allege the agreement included an unlawful "pay for delay" deal.

  5. August 01, 2019

    Amgen, Teva Antitrust MDL Over Sensipar Going To Del.

    The Judicial Panel on Multidistrict Litigation on Wednesday said a Delaware federal court is the best place to centralize four proposed class actions and one individual complaint accusing drug giants Amgen Inc. and Teva Pharmaceuticals USA Inc. of striking an unlawful deal to pull a generic version of the calcium control drug Sensipar off the market.